SAR440340

DRUG2 trials

Sponsors

Sanofi

Conditions

AsthmaChronic Obstructive Pulmonary Disease

Phase 2

Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Participants

CompletedNCT03387852

Start: 2018-03-12End: 2019-08-07Updated: 2022-06-14

Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

CompletedNCT03546907

SanofiChronic Obstructive Pulmonary Disease

Start: 2018-07-16End: 2020-02-21Updated: 2022-11-22

Related Papers

AERIFY-1/2: two phase 3, randomised, controlled trials of itepekimab in former smokers with moderate-to-severe COPD

ERJ Open Research2024-05-0921 citations

A randomised phase 2a study to investigate the effects of blocking interleukin-33 with tozorakimab in patients hospitalised with COVID-19: ACCORD-2

ERJ Open Research2023-08-0910 citations

Itepekimab significantly reduced hospitalizations or emergency department visits in former smokers with moderate-to-severe COPD

2022-09-044 citations

Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma

New England Journal of Medicine2021-10-27371 citations

Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial.

2021-07-21153 citations